Avalo Therapeutics (AVTX) Revenue (2016 - 2025)

Avalo Therapeutics (AVTX) has 10 years of Revenue data on file, last reported at $59000.0 in Q4 2025.

• Quarterly Revenue fell 69.27% year-over-year to $59000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $500000.0 (up 13.38% YoY) and the FY2025 annual result came in at $59000.0, down 86.62% from the prior year.
• Revenue eased to $59000.0 in Q4 2025, from $192000.0 in the prior quarter.
• In the past five years, Revenue ranged from a high of $14.9 million in Q3 2022 to a low of $59000.0 in Q4 2025.
• A 5-year average of $1.7 million and a median of $571000.0 in 2023 frame the typical range for Revenue.
• Annual changes were most pronounced in 2022 — Revenue surged 1007.33% — and 2023, when it sank 98.42%.
• Tracing AVTX's Revenue over 5 years: stood at $219000.0 in 2021, then surged by 309.13% to $896000.0 in 2022, then plunged by 36.27% to $571000.0 in 2023, then slumped by 66.37% to $192000.0 in 2024, then tumbled by 69.27% to $59000.0 in 2025.
• The last three Revenue figures came in at $59000.0 (Q4 2025), $192000.0 (Q4 2024), and $249000.0 (Q3 2024), per Business Quant data.